Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- Author
- GOLD, Ralf1 ; KAPPOS, Ludwig2 ; DAWSON, Katherine T8 ; ARNOLD, Douglas L3 4 ; BAR, Amit4 ; GIOVANNONI, Gavin5 ; SELMAJ, Krzysztof6 ; TORNATORE, Carlo7 ; SWEETSER, Marianne T8 ; YANG, Minhua8 ; SHEIKH, Sarah I8
[1] Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany
[2] Departments of Neurology and Biomedicine, University Hospital Basel, Basel, Switzerland
[3] NeuroRx Research, McGill University, Montreal, Canada
[4] Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
[5] Queen Mary University of London, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United States
[6] Medical University of Lodz, Lodz, Poland
[7] Georgetown University Hospital, Washington, DC, United States
[8] Biogen Idec, Weston, MA, United States
DEFINE Study Investigators - Source
The New England journal of medicine. 2012, Vol 367, Num 12, pp 1098-1107, 10 p ; ref : 21 ref
- CODEN
- NEJMAG
- ISSN
- 0028-4793
- Scientific domain
- General medicine general surgery
- Publisher
- Massachusetts Medical Society, Waltham, MA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Essai clinique phase III Médecine Placebo Récidive Sclérose en plaques Voie orale Maladie inflammatoire Pathologie du système nerveux central Pathologie du système nerveux
- Keyword (en)
- Phase III trial Medicine Placebo Relapse Multiple sclerosis Oral administration Inflammatory disease Central nervous system disease Nervous system diseases
- Keyword (es)
- Ensayo clínico fase III Medicina Placebo Recaida Esclerosis en placa Vía oral Enfermedad inflamatoria Sistema nervosio central patología Sistema nervioso patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17F Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B18 Psychopathology. Psychiatry / 002B18C Adult and adolescent clinical studies / 002B18C13 Organic mental disorders. Neuropsychology
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-D Psychopathology. Psychiatry / 770-D03 Adult and adolescent clinical studies / 770-D03M Organic mental disorders. Neuropsychology
- Discipline
- Generalities in medical sciences Neurology Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 26351306
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1056/NEJMoa1114287 
https://dx.doi.org/10.1056/NEJMoa1114287
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"367\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1098\";s:8:\"\u0000*\u0000epage\";s:4:\"1107\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GOLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ralf\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"KAPPOS, Ludwig\";i:1;s:19:\"DAWSON, Katherine T\";i:2;s:17:\"ARNOLD, Douglas L\";i:3;s:9:\"BAR, Amit\";i:4;s:17:\"GIOVANNONI, Gavin\";i:5;s:17:\"SELMAJ, Krzysztof\";i:6;s:16:\"TORNATORE, Carlo\";i:7;s:20:\"SWEETSER, Marianne T\";i:8;s:12:\"YANG, Minhua\";i:9;s:15:\"SHEIKH, Sarah I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"367\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1098\";s:8:\"\u0000*\u0000epage\";s:4:\"1107\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GOLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ralf\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"KAPPOS, Ludwig\";i:1;s:19:\"DAWSON, Katherine T\";i:2;s:17:\"ARNOLD, Douglas L\";i:3;s:9:\"BAR, Amit\";i:4;s:17:\"GIOVANNONI, Gavin\";i:5;s:17:\"SELMAJ, Krzysztof\";i:6;s:16:\"TORNATORE, Carlo\";i:7;s:20:\"SWEETSER, Marianne T\";i:8;s:12:\"YANG, Minhua\";i:9;s:15:\"SHEIKH, Sarah I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"367\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1098\";s:8:\"\u0000*\u0000epage\";s:4:\"1107\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GOLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ralf\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"KAPPOS, Ludwig\";i:1;s:19:\"DAWSON, Katherine T\";i:2;s:17:\"ARNOLD, Douglas L\";i:3;s:9:\"BAR, Amit\";i:4;s:17:\"GIOVANNONI, Gavin\";i:5;s:17:\"SELMAJ, Krzysztof\";i:6;s:16:\"TORNATORE, Carlo\";i:7;s:20:\"SWEETSER, Marianne T\";i:8;s:12:\"YANG, Minhua\";i:9;s:15:\"SHEIKH, Sarah I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"367\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1098\";s:8:\"\u0000*\u0000epage\";s:4:\"1107\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GOLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ralf\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"KAPPOS, Ludwig\";i:1;s:19:\"DAWSON, Katherine T\";i:2;s:17:\"ARNOLD, Douglas L\";i:3;s:9:\"BAR, Amit\";i:4;s:17:\"GIOVANNONI, Gavin\";i:5;s:17:\"SELMAJ, Krzysztof\";i:6;s:16:\"TORNATORE, Carlo\";i:7;s:20:\"SWEETSER, Marianne T\";i:8;s:12:\"YANG, Minhua\";i:9;s:15:\"SHEIKH, Sarah I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1114287\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"367\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1098\";s:8:\"\u0000*\u0000epage\";s:4:\"1107\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GOLD\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ralf\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"KAPPOS, Ludwig\";i:1;s:19:\"DAWSON, Katherine T\";i:2;s:17:\"ARNOLD, Douglas L\";i:3;s:9:\"BAR, Amit\";i:4;s:17:\"GIOVANNONI, Gavin\";i:5;s:17:\"SELMAJ, Krzysztof\";i:6;s:16:\"TORNATORE, Carlo\";i:7;s:20:\"SWEETSER, Marianne T\";i:8;s:12:\"YANG, Minhua\";i:9;s:15:\"SHEIKH, Sarah I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
